Table 5 Sub-group analysis of the FOG prevalence in general PD patients by the quality of included studies, date of study conduction, and geographical region
Number of studies | Prevalence | 95% CI | P value | Heterogeneity, % | |
|---|---|---|---|---|---|
Quality score | |||||
14-15 | 8 | 40.0% | 31.8-48.2% | < 0.001 | 92.5% |
16-17 | 10 | 39.7% | 32.6-46.8% | < 0.001 | 90.1% |
18-19 | 4 | 40.1% | 28.0-52.3% | < 0.001 | 94.5% |
Geographic region | |||||
Europe | 9 | 41.7% | 34.1-49.4% | < 0.001 | 93.0% |
Asia | 3 | 42.9% | 28.9-56.8% | < 0.001 | 90.7% |
United States | 6 | 33.5% | 22.8-44.2% | < 0.001 | 93.4% |
Australia | 4 | 43.7% | 39.4-48.1% | 0.232 | 30.1% |
Year of study conduction | |||||
2007-2015 | 11 | 40.1% | 33.6-46.6% | < 0.001 | 94.3% |
2016-2019 | 11 | 39.7% | 32.9-46.6% | < 0.001 | 86.0% |